Conduit Pharmaceuticals Inc., previously known as Murphy Canyon Acquisition Corp., has filed a notification of late filing with the SEC for its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company, headquartered at 4995 Murphy Canyon Road, Suite 300, San Diego, CA, cited the inability to compile the necessary financial statements and related disclosures without unreasonable effort or expense as the reason for the delay. Conduit Pharmaceuticals anticipates filing the report by the extended deadline, which is the fifteenth calendar day following the original due date. The company also indicated that there would be a significant change in the results of operations compared to the previous fiscal year due to the business combination and commencement of operations as an operating company since September 2023. The notification was signed by David Tapolczay, Chief Executive Officer, on April 1, 2024.

Conduit Pharmaceuticals Inc., previously known as Murphy Canyon Acquisition Corp., has filed a notification of late filing with the SEC for its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company, headquartered at 4995 Murphy Canyon Road, Suite 300, San Diego, CA, cited the inability to compile the necessary financial statements and related disclosures without unreasonable effort or expense as the reason for the delay. Conduit Pharmaceuticals anticipates filing the report by the extended deadline, which is the fifteenth calendar day following the original due date. The company also indicated that there would be a significant change in the results of operations compared to the previous fiscal year due to the business combination and commencement of operations as an operating company since September 2023. The notification was signed by David Tapolczay, Chief Executive Officer, on April 1, 2024.